As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.
Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma
Latest from Blog
Millions Of Americans Are Driving While Dangerously Tired
WEDNESDAY, Nov. 4, 2026 More than 6 in 10 American drivers admit they ve driven while dangerously sleepy.A new National Sleep Foundation report estimates 145 mi Post Views: 1
Knee Osteoarthritis: Symptoms, Diagnosis And Treatment
WEDNESDAY, Nov. 4, 2026 Knee osteoarthritis (OA) is the most common type of arthritis, affecting about 528 million adults worldwide. It is more than old age or Post Views: 2
Top health takeaways from the midterm elections
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning from a round-the-clock elections team at STAT, where we’ve been closely monitoring
Cutting Away More Healthy Tissue Might Not Meaningfully Reduce Future Cancer Risk
WEDNESDAY, Nov. 4, 2026 Doctors removing cancers surgically might not need to cut away lots of healthy tissue to make sure they ve gotten all the tumor, a new s Post Views:
Expensive Medical Bills Increase Expectations Of Pain During Procedures, Study Says
WEDNESDAY, Nov. 4, 2026 The pain posed to a person s checkbook by a pricey medical procedure might increase their expectations of a physically agonizing ordeal, Post Views: 2